Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid Bedside Test Predicts Sepsis with Over 90% Accuracy

By LabMedica International staff writers
Posted on 28 May 2025

Sepsis is a severe response to an infection that causes the immune system to attack the body's own organs and tissues, potentially leading to organ failure and death if not addressed promptly. More...

It is responsible for approximately 20% of all global deaths. Predicting sepsis remains challenging, as its early symptoms are vague and current diagnostic tests can take up to 18 hours, often requiring specialized labs. This delay in treatment increases the risk of death by nearly 8% per hour. Now, researchers have developed a new blood test and portable device that can detect the onset of sepsis more quickly and accurately than existing methods.

The test, developed by scientists at the University of British Columbia (UBC, Vancouver, BC, Canada) and Sepset Biosciences (Victoria, BC, Canada), has demonstrated over 90% accuracy in identifying individuals at high risk of developing sepsis, marking a significant advancement in how doctors will diagnose and treat this condition. The study, published in Nature Communications, involved analyzing blood samples from more than 3,000 hospital patients with suspected sepsis. Using machine learning, the researchers identified a six-gene expression signature, dubbed "Sepset," which successfully predicted sepsis nine times out of ten, even before a formal diagnosis was made. When tested with an additional 248 blood samples using RT-PCR (Reverse Transcription Polymerase Chain Reaction), a common hospital laboratory technique, the test showed 94% accuracy in detecting early-stage sepsis in patients whose condition was likely to worsen.

This success highlights the powerful role of AI in handling complex data, pinpointing the critical genes necessary for predicting sepsis, and developing a highly accurate algorithm for assessing sepsis risk. To make this test more accessible in clinical settings, the National Research Council of Canada (NRC) has developed a portable device, PowerBlade, which uses a drop of blood and an automated sequence of steps to detect sepsis efficiently. In trials with 30 patients, PowerBlade demonstrated 92% accuracy in identifying patients at high risk of sepsis and 89% accuracy in ruling out those not at risk. The device provided results in under three hours, making it suitable for use in various environments, including emergency rooms and remote healthcare settings.

“Sepsis accounts for roughly 20% of all global deaths,” said lead author Dr. Claudia dos Santos, a critical care physician and scientist at St. Michael’s Hospital. “Our test could be a powerful game changer, allowing physicians to quickly identify and treat patients before they begin to rapidly deteriorate.”

Related Links:
UBC
Sepset Biosciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.